Biomarkers Predictive of a Deucravacitinib Response in PsA A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in PsA suggests specific biologic effects identified by biomarkers may predict clinical responses. https://t.co/zsZl7JQydn https://t.co/4mGBYB4qU4